Tag: Sanofi

Investment will accelerate the overall Sarclisa® development program  Sanofi will continue to fully manage the clinical program and retain full ...

Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER  Specialty Care sales grew 18.3%, driven ...

Q3 2020 sales growth(2) driven by strong Dupixent® and flu vaccines demand. Net sales were €9,479 million, up 5.7%(2) at ...

03 September 2020 London, UK and Paris, France Pre-clinical studies show promising safety and immunogenicity Over 400 participants being enrolled ...

Q2 2020 sales results reflect the strong performance of Dupixent® more than offset by COVID-19 related negative effects on Vaccines, ...

Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system Both companies are committed ...